The authors present a simple way to qualify a swab-sampling procedure for its ability to recover residues of a small-molecule API from cleaned equipment surfaces.
WARUT - STOCK.ADOBE.COM
Spiking studies were specifically designed to assess the impact of sampling parameter variability on swab recoveries. The qualification characteristics included accuracy, precision, linearity, and robustness. An eight-run Plackett-Burman design was used to assess the procedure’s robustness.
Recovery factors for correcting analytical results, taking into account recovery variability, were estimated from the data. The average and individual recoveries for each spiked level were greater than 70%, and the percentage relative standard deviations for overall precision at each spiked level were <20%. The method was found to be robust because none of the factors examined had a statistically significant effect on swab recovery. Results demonstrated that the swab-sampling procedure is suitable for use in cleaning validation.
Regulatory guidance documents currently focus on sampling method effectiveness and demonstrating recovery (3–6). They do not provide specific recommendations on how recovery studies should be designed. A number of different approaches are currently used (7), but methods can be inconsistent, potentially resulting in poorly designed recovery studies, biased results, and misleading recovery factors. The authors research focuses on improving the understanding and assessment of potential sources of variability, presenting a real-world study of sampling methods.
Click herefor a PDF file.
Submitted: October 28, 2019
Accepted: January 3, 2020
Pharmaceutical Technology
Vol. 44, No. 7
July 2020
Pages: 38-45
When citing this article, please refer to it as M. Ovais et al., "Qualification of a Swab Sampling Procedure for Cleaning Validation," PharmTech 44 (7) 2020
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.